Cargando…

Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells

Epigenetic modifications play a major role in the development of multiple myeloma. We have previously reported that the PPARγ agonist pioglitazone (PIO) enhances, in-vitro, the cytotoxic effect of the Histone deacetylase inhibitor (HDACi), valproic acid (VPA), on multiple myeloma cells. Here, we des...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aouali, Nassera, Broukou, Angeliki, Bosseler, Manon, Keunen, Olivier, Schlesser, Vincent, Janji, Bassam, Palissot, Valerie, Stordeur, Philippe, Berchem, Guy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474836/ https://www.ncbi.nlm.nih.gov/pubmed/26091518 http://dx.doi.org/10.1371/journal.pone.0130339

Ejemplares similares

Inhibition of HIF1α-Dependent Upregulation of Phospho-l-Plastin Resensitizes Multiple Myeloma Cells to Frontline Therapy
por: Bosseler, Manon, et al.
Publicado: (2018)

The BET Protein Inhibitor JQ1 Decreases Hypoxia and Improves the Therapeutic Benefit of Anti-PD-1 in a High-Risk Neuroblastoma Mouse Model
por: Sauvage, Delphine, et al.
Publicado: (2022)

Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Barman, Madhumanti, et al.
Publicado: (2021)

Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy
por: Lequeux, Audrey, et al.
Publicado: (2021)

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
por: Giuliani, Massimo, et al.
Publicado: (2017)

The β-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-I-dependent antigen presentation
por: Noman, Muhammad Zaeem, et al.
Publicado: (2022)

Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies
por: Xiao, Malina, et al.
Publicado: (2021)

Bronchial airway gene expression in smokers with lung or head and neck cancer
por: Van Dyck, Eric, et al.
Publicado: (2014)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer
por: Berchem, Guy, et al.
Publicado: (2015)

Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity
por: Janji, Bassam, et al.
Publicado: (2018)

A role for EMT in CD73 regulation in breast cancer
por: Hasmim, Meriem, et al.
Publicado: (2022)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma
por: Schritz, Anna, et al.
Publicado: (2021)

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis, Katherine, et al.
Publicado: (2013)

Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
por: Goehringer, Nils, et al.
Publicado: (2021)

Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34
por: Janji, Bassam, et al.
Publicado: (2020)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

High-dimensional mass cytometry analysis revealed microenvironment complexity in chronic lymphocytic leukemia
por: Wierz, Marina, et al.
Publicado: (2018)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy
por: Benoit, Alice, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Synthesis and Preclinical Evaluation of a Highly Improved Anticancer Prodrug Activated by Histone Deacetylases and Cathepsin L
por: Ueki, Nobuhide, et al.
Publicado: (2016)

Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia
por: Moussay, Etienne, et al.
Publicado: (2010)

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
por: Mottamal, Madhusoodanan, et al.
Publicado: (2015)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Firing up the cold tumors by targeting Vps34
por: Janji, Bassam, et al.
Publicado: (2020)

Histone Deacetylase Activity Modulates Alternative Splicing
por: Hnilicová, Jarmila, et al.
Publicado: (2011)

Human CD56(dim)CD16(dim) Cells As an Individualized Natural Killer Cell Subset
por: Amand, Mathieu, et al.
Publicado: (2017)

Synergistic Anticancer Effect of Glycolysis and Histone Deacetylases Inhibitors in a Glioblastoma Model
por: Pająk, Beata, et al.
Publicado: (2021)

CXCL10 Is an Agonist of the CC Family Chemokine Scavenger Receptor ACKR2/D6
por: Chevigné, Andy, et al.
Publicado: (2021)

Dendritic cell development requires histone deacetylase activity
por: Chauvistré, Heike, et al.
Publicado: (2014)

Reversible histone deacetylase activity catalyzes lysine acylation
por: Tsusaka, Takeshi, et al.
Publicado: (2023)

A potential histone-chaperone activity for the MIER1 histone deacetylase complex
por: Wang, Siyu, et al.
Publicado: (2023)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes
por: Thomas, M. C., et al.
Publicado: (2012)

The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis
por: Li, Jingjing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bdta2hi8mtarcph42l66l11d70